Overall, 57% of participants had evidence on PET/MRI of inflammation affecting the heart or lungs.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
Thirty-day death rates were 8% in the Omicron group, 3% in flu patients, and 6% in the RSV group.
Formulations of the combo vaccines prompted robust immune responses against influenza A, influenza B, and SARS-CoV-2.
Relative to uninfected adults, those with COVID-19 had a 37% higher rate of severe physical symptoms.
Simvastatin had been shown to reduce pulmonary and systemic inflammation in mouse and human models of lung injury.
While antibiotic use at three Chicago hospitals increased in COVID-19 patients at the outset of the pandemic, it declined among non–COVID patients.
Relative vaccine effectiveness was an additional 50% against critical illness.
A second study showed that COVID-19 survivors had higher rates of most studied symptoms than controls, with the greatest risks for shortness of breath, fatigue, memory loss, and headache.
Among critically ill patients, survival to hospital discharge was 62% for the vitamin C group and 65% for the control group.
The effect was especially pronounced in those given convalescent plasma within the first 48 hours of mechanical ventilation.
The study was based on outcomes seen among 660,000 UK patients from February 2020 to April 2021.
